Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats

Psychopharmacology

Volumn 234, Issue 14, 2017, Pages 2207-2217

  Rock, Erin M ^a   Limebeer, Cheryl L ^a   Petrie, Gavin N ^a   Williams, Lauren A ^a   Mechoulam, Raphael ^b   Parker, Linda A ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Anxiety; Anxiolytic; Cannabidiol; Cannabidiolic acid; Foot shock; Light dark emergence test; Rat; Stress; 9 tetrahydrocannabiol

Indexed keywords

CANNABIDIOL; CANNABIDIOLIC ACID; DRONABINOL; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; UNCLASSIFIED DRUG; ANXIOLYTIC AGENT; CANNABINOID; CANNABIS; HTR1A PROTEIN, HUMAN; SEROTONIN; SEROTONIN 1 ANTAGONIST; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANXIETY; ANXIETY ASSESSMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EXPOSURE; FOOTSHOCK; LATENT PERIOD; LIGHT DARK EMERGENCE TEST; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY; ANIMAL; ANXIETY DISORDER; CHEMISTRY; METABOLISM;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; ANXIETY DISORDERS; CANNABIDIOL; CANNABINOIDS; CANNABIS; DRONABINOL; MALE; RATS; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS;

EID: 85018461372     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-017-4626-5     Document Type: Article

References (47)

1. Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F et al (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 36:1219–1226. doi:10.1038/npp.2011.6
2. Berrendero F, Maldonado R (2002) Involvement of the opioid system in the anxiolytic-like effects induced by Δ9-tetrahydrocannabinol. Psychopharmacology 163:111–117. doi:10.1007/s00213-002-1144-9
3. Bitencourt RM, Pamplona FA, Takahashi RN (2008) Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur Neuropsychopharmacol 18:849–859. doi:10.1016/j.euroneuro.2008.07.001
4. Bluett RJ, Gamble-George JC, Hermanson DJ, Hartley ND, Marnett LJ, Patel S (2014) Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. Transl Psychiatry 4:e408. doi:10.1038/tp.2014.53
5. Bolognini D, Rock EM, Cluny NL, Cascio MG, Limebeer CL, Duncan M et al (2013) Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol 168:1456–1470. doi:10.1111/bph.12043
6. Bourin M, Hascoët M (2003) The mouse light/dark box test. Eur J Pharmacol 463:55–65. doi:10.1016/S0014-2999(03)01274-3
7. Brierley DI, Samuels J, Duncan M, Whalley BJ, Williams CM (2016) Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea. Psychopharmacology 233:243–254. doi:10.1007/s00213-015-4100-1
8. Campos AC, Ferreira FR, Guimarães FS (2012) Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors. J Psychiatr Res 46:1501–1510. doi:10.1016/j.jpsychires.2012.08.012
9. Espejo-Porras F, Fernández-Ruiz J, Pertwee RG, Mechoulam R, García C (2013) Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacology 75:155–163. doi:10.1016/j.neuropharm.2013.07.024
10. Fogaça MV, Reis FM, Campos AC, Guimarães FS (2014) Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of 5HT1A receptors and previous stressful experience. Eur Neuropsychopharmacol 24:410–419. doi:10.1016/j.euroneuro.2013.10.012
11. Fokos S, Panagis G (2010) Effects of delta9-tetrahydrocannabinol on reward and anxiety in rats exposed to chronic unpredictable stress. J Psychopharmacol 24:767–777. doi:10.1177/0269881109104904
12. Gomes FV, Reis DG, Alves FH, Corrêa FM, Guimarães FS, Resstel LB (2012) Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT1A receptors. J Psychopharmacol 26:104–113. doi:10.1177/0269881110389095
13. Guimarães FS, Chiaretti TM, Graeff FG, Zuardi AW (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 100:558–559
14. Guimarães FS, de Aguiar JC, Mechoulam R, Breuer A (1994) Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol 25:161–164
15. Hill MN, Gorzalka BB (2004) Enhancement of anxiety-like responsiveness to the cannabinoid CB 1 receptor agonist HU-210 following chronic stress. Eur J Pharmacol 499:291–295. doi:10.1016/j.ejphar.2004.06.069
16. Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJ et al (2015) Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol 25:325–334. doi:10.1016/j.euroneuro.2014.11.014
17. Holmes A (2001) Targeted gene mutation approaches to the study of anxiety-like behavior in mice. Neurosci Biobehav Rev 25:261–273
18. Järbe TU, Andrzejewski ME, DiPatrizio NV (2002) Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol Biochem Behav 73:911–919
19. Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA (1974) Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur J Pharmacol 28:172–177
20. 9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology 218:443–457. doi:10.1007/s00213-011-2342-0
21. Le Foll B, Wiggins M, Goldberg SR (2006) Nicotine pre-exposure does not potentiate the locomotor or rewarding effects of Delta-9-tetrahydrocannabinol in rats. Behav Pharmacol 17:195–199. doi:10.1097/01.fbp.0000197460.16516.81
22. Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T (2010) A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 13:861–876. doi:10.1017/S1461145709990605
23. Martin-Santos R, Crippa JA, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S et al (2012) Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des 18:4966–4979. doi:10.2174/138161212802884780
24. Mechoulam R, Gaoni Y (1965) Hashish—IV: the isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. Tetrahedron 21:1223–1229
25. Moreira FA, Aguiar DC, Guimaraes FS (2006) Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuro-Psychopharmacol Biol Psychiatry 30:1466–1471. doi:10.1016/j.pnpbp.2006.06.004
26. O'Brien LD, Wills KL, Segsworth B, Dashney B, Rock EM, Limebeer CL et al (2013) Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability. Pharmacol Biochem Behav 103:597–602. doi:10.1016/j.pbb.2012.10.008
27. Onaivi ES, Green MR, Martin BR (1990) Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253:1002–1009
28. Patel S, Hillard CJ (2006) Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318:304–311. doi:10.1124/jpet.106.101287
29. Patel S, Hill MN, Hillard CJ (2014) Effects of phytocannabinoids on anxiety, mood, and the endocrine system. In: Pertwee RG (ed) Handbook of cannabis. Oxford University Press, Oxford, pp 189–207
30. Polissidis A, Chouliara O, Galanopoulos A, Rentesi G, Dosi M, Hyphantis T et al (2010) Individual differences in the effects of cannabinoids on motor activity, dopaminergic activity and DARPP-32 phosphorylation in distinct regions of the brain. Int J Neuropsychopharmacol 13:1175–1191. doi:10.1017/S1461145709991003
31. Reilly D, Didcott P, Swift W, Hall W (1998) Long-term cannabis use: characteristics of users in an Australian rural area. Addiction 93:837–846. doi:10.1046/j.1360-0443.1998.9368375.x
32. Resstel LB, Tavares RF, Lisboa SF, Joca SR, Corrêa FM, Guimarães FS (2009) 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 156:181–188. doi:10.1111/j.1476-5381.2008.00046.x
33. Rock EM, Parker LA (2013) Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats. Br J Pharmacol 169:685–692. doi:10.1111/bph.12162
34. Rock EM, Limebeer CL, Parker LA (2015) Effect of combined doses of Δ(9)-tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) on acute and anticipatory nausea using rat (Sprague-Dawley) models of conditioned gaping. Psychopharmacology 232:4445–4454. doi:10.1007/s00213-015-4080-1
35. Rodgers RJ, Haller J, Holmes A, Halasz J, Walton TJ, Brain PF (1999) Corticosterone response to the plus-maze: high correlation with risk assessment in rats and mice. Physiol Behav 68:47–53
36. Rubino T, Sala M, Viganò D, Braida D, Castiglioni C, Limonta V et al (2007) Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral Delta9-tetrahydrocannabinol in rats. Neuropsychopharmacology 32:2036–2045. doi:10.1038/sj.npp.1301330
37. Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic Properties of Cannabidiol at 5-HT1a Receptors. Neurochem Res 30(8):1037–1043
38. Schofield D, Tennant C, Nash L, Degenhardt L, Cornish A, Hobbs C et al (2006) Reasons for cannabis use in psychosis. Aust N Z J Psychiatry 40:570–574. doi:10.1111/j.1440-1614.2006.01840.x
39. Schramm-Sapyta NL, Cha YM, Chaudhry S, Wilson WA, Swartzwelder HS, Kuhn CM (2007) Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats. Psychopharmacology 191:867–877. doi:10.1007/s00213-006-0676-9
40. Song C, Stevenson CW, Guimaraes FS, Lee JL (2016) Bidirectional effects of cannabidiol on contextual fear memory extinction. Front Pharmacol 7:493. doi:10.3389/fphar.2016.00493
41. Thomas H (1993) Psychiatric symptoms in cannabis users. Br J Psychiatry 163:141–149
42. Todd SM, Arnold JC (2016) Neural correlates of interactions between cannabidiol and Δ(9)-tetrahydrocannabinol in mice: implications for medical cannabis. Br J Pharmacol 173:53–65. doi:10.1111/bph.13333
43. Todd SM, Zhou C, Clarke DJ, Chohan TW, BAhceci D, Arnold JC (2017) Interactions between cannabidiol and ∆-9 THC following acute and repeated dosing: rebound hyperactivity, sensorimotor gaiting and epigenetic and neuroadaptive changes in the mesolimbic pathway. Eur Neuropsychopharmacol 27:132–145. doi:10.1016/j.euroneuro.2016.12.004
44. Valjent E, Mitchell JM, Besson MJ, Caboche J, Maldonado R (2002) Behavioural and biochemical evidence for interactions between delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol 135:564–578. doi:10.1038/sj.bjp.0704479
45. Wiley JL, Martin BR (2003) Cannabinoid pharmacological properties common to other centrally acting drugs. Eur J Pharmacol 471:185–193. doi:10.1016/S0014-2999(03)01856-9
46. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76:245–250
47. Zuardi AW, Cosme RA, Graeff FG, Guimarães FS (1993) Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharamcol 7:82–88. doi:10.1177/026988119300700112